The WHO said in a July 26 executive summary it excluded GLP-1 weight loss medications because of “uncertain long-term clinical benefit and safety in this patient population.”.
“Data are lacking on long term effectiveness, optimal duration of treatment, maintenance of weight reduction once the therapy is stopped and effect on other clinically important outcomes,” such as hypertension or hyperglycaemia, the WHO said. “Long-term safety data are also lacking.”
In the revised list, the organization added drugs for multiple sclerosis, numerous infectious diseases, bone cancer and heart disease.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
